Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

41.56 +1.02 (+2.51%)
Delayed Quote Updated: 2:33 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
News headline image
Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega ↗
Alkermes plc (NASDAQ: ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56 
Via Benzinga
News headline image
Earnings Preview: Alkermes ↗
 
Via Benzinga
News headline image
Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor
From Sarissa Capital Management LP
Via Business Wire
News headline image
Where Alkermes Stands With Analysts ↗
 
Via Benzinga
News headline image
Alkermes Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Analyst Expectations for Alkermes's Future ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Alkermes ↗
 
Via Benzinga
News headline image
A Preview Of Alkermes's Earnings ↗
 
Via Benzinga
News headline image
Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
From Sarissa Capital Management LP
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Earnings Scheduled For February 16, 2023 ↗
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
News headline image
Alkermes Earnings Preview ↗
 
Via Benzinga
Analyst Ratings for Alkermes ↗
 
Via Benzinga
News headline image
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance ↗
 
Via Benzinga
News headline image
Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements ↗
 
Via Benzinga
News headline image
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
From Sarissa Capital Management LP
Via Business Wire
News headline image
Alkermes Stock Sees Rising Relative Strength Rating ↗
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
Alkermes: Commercialization Program On Track, Sales Coming In Strong ↗
The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance. 
Via Talk Markets
News headline image
Alkermes Stock Sees Rising Relative Price Strength ↗
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86. 
Via Investor's Business Daily
News headline image
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out ↗
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. 
Via Investor's Business Daily
News headline image
Alkermes's Return On Capital Employed Insights ↗
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q3 sales of $252.36 million. Earnings fell to a loss of $63.97 million, resulting in a 112.28% decrease from last quarter. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Recap: Alkermes Q3 Earnings ↗
Alkermes (NASDAQ:ALKS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Alkermes missed estimated... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>